S
uccessful induction of an immune response to nonreplicating, poorly immunogenic Ags often requires implementation of the vaccine formulation with immunostimulating compounds referred to as adjuvants. Vaccine adjuvants include diverse classes of products, such as mineral salts, microbial products, or liposomes, which have different mechanisms of action (1) .
Although these compounds have been discovered mostly empirically, the recognition of the important role of the innate immune response in determining the magnitude and quality of an adaptive immune response has led to more rational design of immune adjuvants (2, 3) . Accordingly, in light of the recent advances in identifying the receptors responsible for the induction of the innate response (i.e., TLRs), a new generation of adjuvants incorporating these receptor agonists has been engineered for the design of new vaccine formulations (2, 4) . Whereas TLRs recognize non-self motifs of infectious micro-organisms, another class of intracellular receptors called nucleotide-binding oligomerization domain-like receptors (NLRs) senses stimuli of microbial origin as well as endogenous danger signals (ATP and uric acid) (5, 6) . The most studied member of NLR is NLRP3 (NRL family, pyridin domain-containing 3), which, together with apoptosis-associated speck-like protein containing a caspase recruitment domain and caspase-1, forms the inflammasome multiprotein platform for the processing of the proform of IL-1b or IL-18 (7, 8) . The NLRP3 inflammasome is activated by the widely used clinical adjuvant aluminium salt (alum) (9) (10) (11) (12) (13) (14) and has been reported to participate in alum adjuvanticity (9, 11) , although this is still a matter of debate (15) .
The discovery of sensors able to detect self molecules that are associated with infection or cell damage secondary to chemical and/or physical insult helps to understand why, under certain circumstances, such as inflammation secondary to tissue damage, an immune response can be generated in the apparent absence of any "foreign" Ag. It has been postulated that in these situations the immune system is able to detect the consequences of a potentially harmful situation by reacting to danger signals expressed or released by stressed cells. In keeping with this concept, uric acid, a component released by dying cells, demonstrated adjuvant properties in vivo when coinjected with Ag (16) .
Several observations suggest that metabolic stress also may be linked to the development of an immune response. Numerous clinical examples illustrate the occurrence of metabolic disorders (such as weight loss) associated with infection (17) . The altered metabolism observed during infection has been interpreted generally as a consequence of the high energetic cost of an immune response. However, a series of observations suggest that pathogens can directly regulate metabolic responses. Rotavirus infection of an intestinal cell line (Caco-2) leads to metabolic dysfunction characterized by increased production of lactate, decreased mitochondrial function, and reduced intracellular ATP content (18) . Viral mitochondria-localized inhibitor of apoptosis, a mitochondria-localizing protein encoded by the human CMV genome, also has been shown to inhibit ATP synthesis in infected cells, causing lower steady state ATP levels (19) . Finally, Madin-Darby canine kidney cells infected by H1N1 influenza variants display reduced intracellular ATP levels and increased glucose uptake indicative of a specific energetic burden for infected cells (20) . On the basis of these observations, we hypothesized that ATP depletion, secondary to infection or another metabolic stress, could be sensed by immune cells and initiates a cascade of events ultimately leading to an increased immune response. In the present work, we explore the effect of drugs known to deplete intracellular ATP on the immune response in vivo. We demonstrate herein that compounds known to interfere with cellular metabolism increase the humoral response to coinjected Ags. Notably, these drugs do not induce a detectable inflammatory response in vivo, suggesting a novel strategy for the development of low-toxicity adjuvants able to increase humoral responses in vivo with minimal reactogenicity.
Materials and Methods
Mice and reagents C57BL/6 and BALB/c mice were purchased from Harlan Nederland (Horst, The Netherlands). IL-6 2/2 mice were purchased from The Jackson Laboratory (Bar Harbor, ME). Caspase-1 knockout (KO) mice have been described previously (21) . Dr. S. Akira (Osaka University, Osaka, Japan) and Dr. B. Viollet (Institut Cochin, Paris, France) kindly provided the MyD88 and AMP-activated kinase (AMPK) a1 strains, respectively. All of the mice were used at 6-12 wk of age. The experiments were performed in compliance with the relevant laws and institutional guidelines and were approved by the local committee.
The oligomycin was a mixture of oligomycins A, B, and C and was obtained from Sigma-Aldrich (St. Louis, MO; catalog no. 04876). 5-Aminoimidazole-4-carboxamide-1-b-D-ribonucleoside (AICAR) was purchased from Sigma-Aldrich and Toronto Research Chemicals (Toronto, Ontario, Canada). Metformin (dimethylbiguanide; D5035) was from SigmaAldrich. All of these compounds were found to be negative for endotoxin content by the Limulus amebocyte lysate assay (Lonza). Imject Alum was from Thermo Scientific Pierce (Rockford, IL).
Humoral response
Ags used throughout this study were 4-hydroxy-3-nitrophenylacetyl keyhole limpet hemocyanin (NP-KLH), NP-Ficoll (Biosearch Technologies), arsonate-coupled KLH (produced in house), HPV16-E7 protein (kindly provided by J.-M. Brulet, Laboratory of Chemical Biology, Université Libre de Bruxelles, Gosselies, Belgium), or human g globulins (Sigma-Aldrich). Mice were immunized by injecting 50-100 mg of Ag (primary response) and challenged 2 or 3 wk later with the same amount of Ag (secondary response). Serum levels of Ag-specific Abs were determined by ELISA using mouse isotype-specific rat mAbs, (Lo-Imex, Bruxelles, Belgium), as described previously (22) . Lo-Imex anti-isotype Abs used throughout this study were LoMG1-13-HRP (mouse IgG1), LoMG2A-9-HRP (mouse IgG2a), LoMG3-13-HRP (mouse IgG31), LoMM-9-HRP (mouse IgM), and LoME-2-HRP (mouse IgE).
Cell purification

CD4
+ T cells were purified from naive animals by magnetic depletion of B cells, macrophages, dendritic cells (DCs), NK cells, granulocytes, erythroid precursors, and CD8 + T cells. CD62L + CD4 + T cells were purified further by magnetic separation using biotin-coupled anti-CD62L mAbs (eBioscience) and anti-biotin-conjugated magnetic beads (Miltenyi Biotec, Bergisch Gladbach, Germany). Separation was performed on an autoMACS column using the PosselD program, according to the manufacturer's instructions. Cell cultures were performed in RPMI 1640 supplemented with 5% FCS, penicillin, streptomycin, glutamine, nonessential amino acids, 1 mM sodium pyruvate, and 5 3 10 25 M 2-ME. Bone marrow-derived dendritic cells (BMDCs) and bone marrowderived macrophages (BMDMs) were generated as follows. Frozen bone marrow cells were plated at a concentration of 2 3 10 5 cells per milliliter in medium supplemented with 10 ng/ml GM-CSF (BMDCs) or 20% supernatant of L929 cells (BMDMs) in six-well plates in a volume of 6 ml. At days 3 and 6, 4 ml of supernatant was replaced by 4 ml of fresh medium containing growth factors. At day 9, cells were collected, centrifuged, and resuspended in fresh medium (1-2 3 10 5 cells per 96 wells) in the presence of the indicated dose of stimuli.
ATP measurement
Cells were incubated for 4-6 h in the presence of oligomycin, solvent (DMSO), or AICAR. After centrifugation, cells pellets were lysed in radioimmunoprecipitation assay buffer (to measure protein content) or in ATPreleasing reagent (to measure ATP content). ATP concentration was measured by chemiluminescence using a commercially available kit (ATP bioluminescence somatic cell assay kit: FL-ASC; Sigma-Aldrich) following the manufacturer's instructions.
Flow cytometry
Specific cell-surface staining was performed using a standard procedure with the following Abs: PE-anti-MHC class II (clone 14.4.4; BD Pharmingen), FITC-anti-CD80 (clone 16.10A1; eBioscience), and FITC-anti-CD86 (clone GL1; eBioscience). CFSE (Molecular Probes) labeling and in vivo cell division monitoring were performed as described previously (23) .
Cytokine detection
IL-4 and IFN-g production was measured in the supernatants of T cells by ELISA using specific matched paired Abs: IL-4 capture Ab, clone 11B11 (produced in house), detection Ab, biotinylated anti-IL-4/avidin-HRP (eBioscience); IFN-g capture Ab, clone Db-1, detection Ab, clone F1, kindly provided by P.H. Van Der Meide (Netherlands Organisation for Applied Scientific Research, Rijswijk, The Netherlands) and Dr. A. Billiau (Katholieke Universiteit Leuven, Leuven, Belgium), respectively. For intracellular cytokine staining, Th cells were stimulated for 72 h with plasticcoated anti-CD3 mAbs in the presence of AICAR. Cells were recovered and restimulated with ionomycin and PMA in the presence brefeldin A (2 mg/ml; Sigma-Aldrich) for an additional 4 h. Cells were resuspended in Fixation/Permeabilization solution (BD Cytofix/Cytoperm kit; BD Pharmingen), and intracellular cytokine staining was done according to the manufacturer's protocol. IL-21 production was determined using recombinant mouse IL-21R subunit/Fc Chimera (R&D Systems) and PE-goat anti-human IgG (Jackson ImmunoResearch). Flow cytometric analysis was performed using a FACSCanto II flow cytometer (BD Biosciences, Mountain View, CA).
Immunohistochemistry
Immunohistochemistry was performed as described previously (24) . Briefly, spleens were fixed in ImmunoHistoFix (Aphase, Nassogne, Belgium), embedded in ImmunoHistoWax (Aphase), and sectioned at 3-6 mm. The sections were treated for 30 min at room temperature with blocking reagent (1% in PBS; Boehringer, Ingelheim, Germany), washed in PBS, treated with 3% H 2 O 2 in PBS for 30 min at room temperature to block endogenous peroxidase, washed, and stained with FITC-anti-CD90 (clone HO13.4), FITC-anti-CD11c (clone N-418), and/or biotinylated anti-CD45RB (clone B220) mAbs (all produced in-house) for 2-3 h at room temperature. The slides were washed further in PBS, incubated with avidin-biotin-HRP complex (Vectastain ABC kit; Vector Laboratories, Burlingame, CA) and/or anti-fluorescein-alkaline phosphatase (Roche, Mannheim, Germany) for 30 min at room temperature, and washed in PBS. The alkaline phosphatase activity was revealed in blue using Substrate Kit III from Vector Laboratories. The peroxidase activity was revealed using amino-3-ethyl-9-carbazole (Sigma-Aldrich) giving red precipitates. Slides were mounted in Aquatex (Merck, Darmstadt, Germany), and digitized images were captured with Leica DM 4000B (Varhaw Scientific, Norcross, GA) and analyzed with Adobe Photoshop (San Jose, CA).
Statistical analysis
Statistical analysis was performed using Prism (GraphPad Software, San Diego, CA). An unpaired Student t test or one-way ANOVA was used where appropriate. A p value ,0.05 was considered significant.
Results
Oligomycin increases Ag-specific Ab secretion when coadministered with Ag in vivo
Oligomycin represents a well characterized mitochondrial ATP synthase inhibitor, known to decrease intracellular ATP levels in cells relying on oxidative phosphorylation for energy metabolism. As for many quiescent cells, the intracellular ATP pool of resting lymphocytes in vivo is generated largely by oxidative phosphorylation of a diverse set of substrates, including glucose, lipids, and amino acids. To demonstrate the ability of oligomycin to interfere with normal ATP biosynthesis in vivo, mice were injected in the foot pads with a nonlethal dose of oligomycin (0.5 mg/kg), and draining lymph nodes were collected 5 h later for determination of intracellular ATP levels. As shown in Fig. 1C , oligomycin led to a significant reduction in lymphocyte ATP levels when administered in vivo. We next wished to examine the effect of oligomycin on an in vivo immune response when coadministered with Ag. BALB/c mice were injected with a T cell-dependent (NP-KLH) or T cellindependent (NP-Ficoll) Ag mixed with oligomycin (0.5 mg/kg) or solvent (DMSO) and assayed for Ag-specific Ab secretion. Secretion of IgG1, IgG2a, and IgG3 against NP were increased above control (DMSO) values in the oligomycin-treated group and reached statistically significant differences during secondary responses, whereas IgM levels were not affected significantly by this immunization protocol (Fig. 1A) , suggesting that oligomycin treatment promoted humoral responses against the T celldependent Ag. In contrast, oligomycin only barely affected Ab secretion in response to a T cell-independent Ag, as shown in Fig.  1B .
Oligomycin increases humoral responses independently of NLRP3 inflammasome activation and IL-6 secretion
Mitochondrial dysfunction induced by oligomycin has been shown to promote reactive oxygen species production (25) . Alternatively, oligomycin could induce cell damage, leading to the release of markers such as ATP or uric acid. Because both reactive oxygen species and the endogenous danger signals ATP and uric acid have been shown to activate the NALP3 (NACHT, LRR, and PYD domains-containing protein 3) inflammasome (26, 10), we tested whether oligomycin-induced Ab secretion relied upon a functional, IL-1b-releasing, NALP3 inflammasome. Mice inoculated i.p. with oligomycin or control (DMSO) did not secrete IL-1b in their peritoneal exudates ( Fig. 2A) . Accordingly, neither BMDMs nor BMDCs released IL-1b in the presence of LPS and oligomycin (Fig. 2B) . As a positive control, alum treatment elicited the secretion of a significant amount of IL-1b both in vivo ( Fig. 2A ) and in vitro (Fig. 2B) . To further exclude a role for the NALP3 inflammasome in the adjuvanticity of oligomycin, control and caspase-1-deficient mice were inoculated with NP-KLH in the presence or absence of oligomycin, as described in Fig. 1 . Oligomycin enhanced anti-NP IgG secretion in both wild-type (WT) and capase-1 KO mice (Fig. 2C ). This result suggests that oligomycin promotes increased humoral responses independently of caspase-1-dependent inflammasomes.
IL-6 is a pleiotropic cytokine produced by lymphoid and nonlymphoid cells that plays a major role in the differentiation of follicular Th cells (27) (28) (29) . In addition, several adjuvant formulations were shown to differ widely in their requirement for IL-6 during in vivo priming of humoral responses (30) . We therefore immunized WT and IL-6-deficient mice with Ag in control (DMSO) or oligomycin-containing solution. In the absence of adjuvant, IL-6 KO mice secreted a reduced amount of NP-specific Abs compared with the WT mice (Fig. 2E , white histograms), in agreement with previous reports (31) . However, oligomycin coinjection with NP-KLH elicited a strong increase in Ab titers in both WT and IL-6 KO mice, suggesting an IL-6-independent mechanism for the humoral responses induced by oligomycin.
AICAR augments humoral responses in vivo
Although the pharmacological and toxicological properties of oligomycin have not been investigated fully, this natural antibiotic is toxic in vitro and in vivo, with a reported LD 50 in mice of 1.5 mg/kg when injected i.p. (see Material Safety Data Sheets available from several suppliers, including Santa Cruz Biotechnology at http://datasheets.scbt.com/sc-201551.pdf). To evaluate the possibility of translating our previous observations into a clinical setting, we searched the literature for compounds known to induce metabolic stress but displaying reduced toxicity in vivo. AICAR Recently, this compound has been shown to cause a significant decrease in intracellular ATP levels in several human and murine cell lines (32) (33) (34) . Despite the lack of precise information concerning its mode of action, AICAR has been used extensively in animals and human clinical studies as a putative agent thought to protect the heart, lung, and small intestine against ischemic damage (35, 36) , and the safety, tolerance, and pharmacokinetics of this compound are well described (37) . The ability of AICAR to increase T cell-dependent humoral responses in vivo therefore was evaluated. BALB/c mice were injected i.p. with saline, AICAR (10 mg per mouse, containing ,1 U/ml endotoxin), NP-KLH in saline, or NP-KLH in AICAR solution. Mice were bled 10 d after a primary injection, and Ag-specific Ab levels were determined by ELISA. The experiment depicted in Fig. 3A illustrates the ability of AICAR, similar to oligomycin, to increase the primary Ab response to a coinjected Ag. AICAR alone did not induce an Ag-specific response, nor did it affect total serum Ig levels (data not shown). As observed previously with oligomycin, AICAR failed to increase the humoral response to a T cell-independent Ag (data not shown). To confirm the role of the CD4 + T cell compartment in the adjuvanticity of AICAR, mice were treated or not with the anti-mouse CD4-depleting Ab and injected i.p. with Ag in saline or AICAR. Results presented in Fig. 3B showed that AICAR did not augment the Ag-specific Ab response in the absence of CD4-expressing T cells. Accordingly, coadministration of AICAR with arsonatecoupled KLH (Ars-KLH) Ag led to increased levels of Ag-specific IgG but only barely affected the level of IgM Abs (Fig. 3E) . IgE secretion was not affected significantly by AICAR administration in this model (Supplemental Fig. 1 ). AICAR increased IgG Ab secretion during both primary and secondary responses against a different set of Ags: proteins (human g globulins and HPV16-E7 protein; Fig. 3C, 3D ) or haptens (arsonate and NP; Fig. 3A, 3B, 3E) . Finally, to evaluate the ability of AICAR to induce a long-term memory response, mice inoculated with Ars-KLH in saline or in AICAR solution were challenged with the same Ag in saline and tested for Ag-specific Abs 100 d after secondary injection. As control, a third group of mice received the same amount of Ag in alum. Notably, both alum and AICAR were able to induce a longlasting immune response as witnessed by the high titers of Agspecific IgG1 and IgG2a Abs found in the serum of mice bled 100 d after secondary injection (Fig. 3E) .
Because the antidiabetic drug metformin, which also is used widely in clinical settings, was shown recently to induce a decrease in ATP concentration both in vitro and in vivo in muscle and hepatocytes (38-41), we tested whether this compound could exert similar adjuvancity effects in our experimental model. Mice inoculated with Ars-KLH in the presence of metformin secreted more hapten-specific IgG Abs compared with solvent/Ars-KLHinoculated mice (Supplemental Fig. 2 ), suggesting that distinct compounds that share the ability to decrease intracellular ATP levels display adjuvant properties when coinjected with an Ag.
Lack of inflammatory response to AICAR administration
We next evaluated the local inflammatory response induced in mice by coadministration of AICAR and Ag. PBS, AICAR, or alum was administered s.c. into the foot pad of naive mice, and the site of injection was analyzed for the presence of infiltrating granulocytes. Histological studies indicated that, in contrast to alum, AICAR and PBS injection only caused limited recruitment of granulocytes to the injection site (Supplemental Fig. 3) . Accordingly, injection of AICAR or PBS led to the limited enlargement of draining lymph nodes when compared with the significant cellular influx observed in response to alum (Fig. 4A) . AICAR administration did not result in increased cell apoptosis/necrosis in the draining lymph nodes examined at different time points (20 h, 3 d, and 7 d), as judged by annexin V and propidium iodide staining (Supplemental Fig. 4) . AICAR also was assayed for the ability to induce DC migration in vivo, as described previously (42) (43) (44) . Most DCs, identified by the CD11c marker, were found in the splenic marginal zones and around the central arterioles of control, untreated animals (Fig. 4B, top panels) . Injection of LPS led to the rapid (6 h posttreatment) redistribution of DCs to the white pulp, in T cellrich areas surrounding the central arteriole (Fig. 4B, bottom panels) . In marked contrast, AICAR injections failed to affect DC migration (Fig. 4B , middle panels) and maturation (data not shown) in vivo. Accordingly, AICAR did not promote DC maturation in vitro as assessed by FACS analysis of expression of CD80, CD86, or MHC class II molecules (Fig. 4C) . Moreover, AICAR promoted humoral responses in MyD88-deficient mice (Supplemental Fig. 5 ) and did not elicit detectable IL-1b ( Fig. 2A) , IL-6, or high mobility group box 1 (data not shown) secretion or release in vivo. Collectively, these observations are in keeping with the putative antiinflammatory properties of AICAR in vivo and indicate that this compound is able to increase humoral responses in vivo without promoting DC activation and/or inflammation.
AICAR promotes IL-4 and IL-21 secretion in vitro
In an attempt to identify the possible link between metabolic stress and humoral responses, splenocytes purified from naive mice were exposed in vitro to graded doses of AICAR and oligomycin. Small concentrations of oligomycin (1-10 nM) led to .40% reduction in ATP content over a few hours (Fig. 5A and data not shown) and ended with cell death after 24 h, precluding the use of this metabolic stressor for in vitro experiments. As reported previously (32) (33) (34) , concentrations of AICAR .500 mM led to .50% reduction in ATP concentrations (Fig. 5B ) and also were found to be toxic for T cells (data not shown). However, concentrations of 125-250 mM AICAR did not affect T cell viability while modestly (10-30%) but significantly reducing ATP content (Fig. 5B) . Splenocytes from BALB/c or DO11.10 mice were stimulated with selected T or B cell agonists in the presence or absence of AICAR, and proliferation was monitored by CFSE dilution. As shown in Fig. 5C and 5E, AICAR promoted CD4 + T cell division (shift toward low CFSE contents) after stimulation in both an Ag/APC-and an APCindependent, anti-CD3 mAbs-mediated, fashion. Interestingly, AICAR did not affect anti-CD3-triggered CD8 + T cell proliferation or anti-IgM-mediated B cell division (Fig. 5D, 5F , respectively), suggesting that AICAR might selectively affect CD4 + T cell activity in vitro. CD4 + CD62L
+ T lymphocytes therefore were activated by anti-CD3/anti-CD28 mAbs in the presence of AICAR or control medium and tested for cytokine secretion. Results presented in Fig. 5G and 5H show that AICAR promoted IL-4 production in Th cells, as judged by both ELISA and intracellular cytokine staining. IFN-g was either unaffected or slightly inhibited in these cultures (Fig. 5G, 5H ). Because IL-21 played an important role in B cell activation and IgG class switch, we tested whether AICAR could modulate its production. Of interest, AICAR also enhanced IL-21 secretion by T cells, reaching levels similar to those of the positive (IL-6-treated cells) control (Fig. 5I, 5J ). This result was confirmed by RT-PCR (data not shown), whereas IL-10 and IL-17 were not detected in these experimental conditions (data not shown). A, Mice were inoculated with 100 mg NP-KLH, 5 mg AICAR, or both and tested for NP-specific IgG on day 10. B, Mice were treated or not with anti-CD4 Abs (clone GK1.5; two i.p. injections of 1 mg on days 0 and 5). On day 2, mice were injected i.p. with NP-KLH with or without AICAR. Ten days after immunization, mice were tested for serum levels of NP-specific IgG Abs. C and D, Mice were inoculated with human g globulins (HGG; 15 mg, C) or HPV16-E7 (10 mg, D) with saline or AICAR. Mice in C received a second Ag injection in saline on day 21. Ag-specific isotypes were determined at the indicated timings. E, Three groups of mice received an i.p. injection of Ars-KLH (100 mg) in saline, AICAR solution, or Alum. All of the mice were challenged with Ars-KLH in saline on day 21. Serum levels of Ars-specific Abs were determined on day 100 after challenge. Results represent individual Ab titers and the mean 6 SD Ab concentration for each group of mice. Results are representative of at least two independent experiments. *p , 0.05, **p , 0.01, ***p , 0.001.
Discussion
We provide herein evidence that compounds affecting cell metabolism enhance humoral responses in vivo when coinjected with a protein Ag. Both oligomycin and AICAR have been shown to effectively increase humoral responses to several T cell-dependent Ags, such as haptenylated proteins (Ars-KLH and NP-KLH) and nonhaptenylated proteins of eukaryotic (OVA and human g globulin) or viral (HPV16-E7) origin (Figs. 1-3, Supplemental  Fig. 5, and data not shown) . Noteworthy, the immune response to T cell-independent Ags (such as NP-Ficoll) was not affected by these metabolic inhibitors, suggesting that these compounds exert their adjuvant capacity by modulating T cell responses. In keeping with this hypothesis, 1) IgM secretion was barely affected by AICAR/oligomycin treatments (Figs. 1, 3 , and data not shown); 2) Igs of the IgG isotype are detected rapidly during the primary response in animals treated with Ag and AICAR or oligomycin formulations (Figs. 2, 3) ; and finally, 3) in vivo CD4 + T cell depletion counteracts the adjuvant properties of AICAR (Fig. 3) . On the basis of the assumption that most adjuvants increase adaptive immune responses (and in particular T cell-regulated responses) by activating the innate immune compartment, a detailed in vitro and in vivo analysis of the effect of AICAR/oligomycin on dendritic cell biology was undertaken. Despite numerous efforts, no evidence of dendritic cell activation/maturation upon AICAR or oligomycin treatment was found (Fig. 4, Supplemental Fig. 5 , and data not shown), suggesting that these compounds did not promote or affect an innate immune response mediated by dendritic cells. It is also noteworthy that when injected AICAR provoked only limited cellular recruitment in lymph nodes draining the injected site (Fig. 4) , suggesting a markedly reduced effect of this compound on the innate response when compared with that of other adjuvants such as alum. Although we did not perform a through full examination of the effects of AICAR and oligomycin on all of the cellular components of the innate response, the adjuvant effect of these compounds did not require caspase-1 or MyD88 expression in vivo (Fig. 2, Supplemental Fig. 5, respectively) , indicating that their ability to increase humoral responses was independent of these important innate signaling pathways. The finding that caspase-1 is not required for oligomycin to promote Ag-specific humoral responses is in line with recent reports on inflammasome-independent Ab responses driven by alum or microparticles (13, 14, 45) and, together with the lack of role for MyD88, argues against a putative role for cell death-dependent signaling molecules (such as uric acid, high mobility group box 1, or any other IL-1b-dependent signaling molecule) in mediating the adjuvant effects of this drug.
The restricted ability of AICAR to promote T cell-dependent responses led us to examine its immunomodulatory properties on purified naive CD4 + T cells stimulated in an APC-independent fashion. Addition of AICAR at the time of TCR stimulation slightly enhanced cell proliferation and led to a selective increase in IL-4 and IL-21 secretion (Fig. 5) , suggesting that AICAR might promote the development of Th2 and/or follicular Th cell subsets, two T cell populations endowed with B cell helper capacities both in vitro and in vivo (27, 29, (46) (47) (48) . In particular, IL-21 has been described widely as a cytokine promoting IgG class switch in B lymphocytes in numerous in vitro and in vivo experimental models (49) (50) (51) .
Our observations concur with those of Nath et al. (52), who recently reported the anti-inflammatory properties of AICAR in a mouse model of experimental autoimmune encephalomyelitis. In that study, AICAR was found to inhibit secretion of the Th1 type cytokines IFN-g and TNF-a while promoting the production of the Th2 cytokines IL-4 and IL-10. Although we have not observed strong inhibition of the Th1 response in our in vitro settings, our data are in keeping with studies showing that AICAR might promote anti-inflammatory responses (52) (53) (54) (55) (56) and suggest that humoral responses could be induced in vivo in the absence of inflammatory reaction.
Oligomycin and AICAR have been reported as strong activators of AMPK, an evolutionary conserved serine-threonine kinase that regulates the cellular energy balance (intracellular AMP/ATP ratio) upon metabolic stress, by inhibiting ATP-consuming processes and stimulating ATP-generating pathways (57) . Although most cell types express both a1 and a2 catalytic isoforms, lymphoid cells only express the AMPKa1 catalytic subunit (58, 59) . We have shown previously that AMPKa1 enables lymphocytes to adapt to failing mitochondrial activity in vitro and represents an important enzyme allowing lymphocytes to resist to a mild energy crisis (59) . In agreement with these data, we observed that AMPKa1-deficient mice displayed increased sensitivity to oligomycininduced metabolic stress in vivo as reflected by enhanced mortality in response to higher doses of oligomycin injection (F. Andris, unpublished observations). However, AMPKa1 activation The Journal of Immunologydid not seem to be required for oligomycin-induced Ab secretion in our experiment settings, because both WT and AMPKa1-deficient mice secreted higher levels of Ag-specific Abs after immunization in the presence of a nontoxic dose of oligomycin (data not shown). Further experiments will be required to test whether the expression of AMPKa2 in the nonlymphoid cell compartment would be implicated in the adjuvant effect of oligomycin.
Although AICAR and oligomycin are strong activators of AMPK, they might induce other intracellular signaling pathways. In support of this assumption, Guigas et al. (33) recently reported that inhibition of glucose phosphorylation by AICAR, metformin, and oligomycin was due to an AMPK-independent but ATP depletion-dependent defect in glucokinase translocation. Although the mechanism by which AICAR affects intracellular ATP levels remains to be firmly established, its rapid phosphorylation upon cellular uptake is likely to cause a transient reduction in available ATP. To further examine the possible relationship between reduced ATP levels and adjuvant activity in vivo, the antidiabetic drug metformin, which was shown to induce a decrease in ATP concentration both in vitro and in vivo in muscle and hepatocytes (38) (39) (40) (41) , was coinjected with Ars-KLH and similarly found to promote hapten-specific IgG Ab secretion. (Supplemental Fig. 2) .
Collectively, these observations indicate that structurally unrelated compounds that share the ability to decrease intracellular ATP levels display adjuvant properties when coinjected with an Ag. It is therefore tempting to speculate that metabolic stress may represent a novel danger signal, leading, by a yet undefined mechanism, to an increased immune response. In support of this idea, recent data demonstrate that metformin enhances the survival of CD8
+ memory T cells through the modulation of cell metabolism (60) . Whether intrinsic changes in the metabolism of CD4 + Th cells also lead to the enhancement of immune responses warrants further investigations.
Finally, several clinical trials, designed to evaluate the antiinflammatory effect of AICAR in preventing the adverse effects of a coronary artery bypass graft, demonstrated that this drug was well tolerated in humans, with no apparent side effects (35, 36) . Therefore, although additional work is required to understand the molecular mechanism by which AICAR promotes the development of T cells endowed with B cell helper capacity, the present approach may pave the way to novel and safer adjuvants to promote humoral responses in vivo.
